BiogenBIIB
About: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Employees: 7,605
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
23% more repeat investments, than reductions
Existing positions increased: 324 | Existing positions reduced: 263
21% more first-time investments, than exits
New positions opened: 126 | Existing positions closed: 104
1% more funds holding
Funds holding: 855 [Q4 2024] → 861 (+6) [Q1 2025]
3.56% less ownership
Funds ownership: 90.14% [Q4 2024] → 86.58% (-3.56%) [Q1 2025]
14% less capital invested
Capital invested by funds: $20.1B [Q4 2024] → $17.3B (-$2.76B) [Q1 2025]
44% less call options, than puts
Call options by funds: $345M | Put options by funds: $621M
50% less funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 2 (-2) [Q1 2025]
Research analyst outlook
12 Wall Street Analysts provided 1 year price targets over the past 3 months
12 analyst ratings
Piper Sandler David Amsellem | 13%downside $115 | Neutral Reiterated | 12 Jun 2025 |
Wedbush Laura Chico | 9%downside $121 | Neutral Reiterated | 12 Jun 2025 |
Mizuho Salim Syed | 28%upside $169 | Outperform Maintained | 7 May 2025 |
JP Morgan Chris Schott | 32%upside $175 | Neutral Maintained | 5 May 2025 |
RBC Capital Brian Abrahams | 55%upside $205 | Outperform Maintained | 2 May 2025 |
Financial journalist opinion
Based on 6 articles about BIIB published over the past 30 days









